Protein-Protein Interactions in Neurodegeneration

Migration, Crosslink

📖

Protein-Protein Interactions in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-protein-protein-interact

📖 Wiki Page

mechanism1708 wordssynced 2026-04-02

Protein-Protein Interactions in Neurodegeneration

Protein-protein interactions (PPIs) form the molecular basis of pathological cascades in neurodegenerative diseases. This hub aggregates key interactions relevant to Alzheimer's Disease, Parkinson's Disease, ALS, and Frontotemporal Dementia. Understanding these interactions reveals the mechanistic foundations of protein aggregation, signal transduction, and cellular dysfunction that drive disease progression.

Key Interaction Pairs

flowchart TD Protein_Protein_Interactions_i["Protein-Protein Interactions in Neurodegeneratio"] Protein_Protein_Interactions_i["Protein-Protein"] Protein_Protein_Interactions_i -->|"related to"| Protein_Protein_Interactions_i style Protein_Protein_Interactions_i fill:#81c784,stroke:#333,color:#000 Protein_Protein_Interactions_i["PPIs"] Protein_Protein_Interactions_i -->|"related to"| Protein_Protein_Interactions_i style Protein_Protein_Interactions_i fill:#81c784,stroke:#333,color:#000 Protein_Protein_Interactions_i["form"] Protein_Protein_Interactions_i -->|"related to"| Protein_Protein_Interactions_i style Protein_Protein_Interactions_i fill:#81c784,stroke:#333,color:#000 style Protein_Protein_Interactions_i fill:#4fc3f7,stroke:#333,color:#000

...

Protein-Protein Interactions in Neurodegeneration

Protein-protein interactions (PPIs) form the molecular basis of pathological cascades in neurodegenerative diseases. This hub aggregates key interactions relevant to Alzheimer's Disease, Parkinson's Disease, ALS, and Frontotemporal Dementia. Understanding these interactions reveals the mechanistic foundations of protein aggregation, signal transduction, and cellular dysfunction that drive disease progression.

Key Interaction Pairs

Mermaid diagram (expand to render)

| Interaction | Diseases | Functional Context | Pathway |
|-------------|----------|---------------------|---------|
| [SNCA](/proteins/alpha-synuclein)—[TUBB](/proteins/tubulin) | PD, DLB, MSA | Tubulin polymerization, Lewy body formation | [alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) |
| [MAPT](/proteins/tau)—[GSK3B](/entities/gsk3-beta) | AD, PSP, CBD | Tau hyperphosphorylation, NFT formation | [Tau Phosphorylation Pathway](/mechanisms/tau-phosphorylation-pathway) |
| LRRK2—[14-3-3](/proteins/14-3-3-protein) | PD, PSP | Kinase regulation, subcellular localization | [LRRK2 Pathway](/mechanisms/lrrk2-pathway-parkinsons) |
| [APP](/proteins/app-amyloid-precursor-protein)—[APBB1](/entities/apbb1) (Fe65) | AD | Amyloid processing, transcriptional regulation | [APP Amyloid Pathway](/mechanisms/app-amyloid-pathway-alzheimers) |
| [TARDBP](/proteins/tdp-43-protein)—[FUS](/proteins/fus-protein) | ALS, FTD | RNA processing, stress granules | [ALS TDP-43 Pathway](/mechanisms/als-tdp43-pathway) |

SNCA-TUBB Interaction

α-Synuclein is a 140-amino acid protein encoded by the SNCA gene, predominantly expressed in presynaptic terminals of neurons[@sncamembrane]. Under normal conditions, α-synuclein binds to β-tubulin and γ-tubulin, promoting microtubule assembly and regulating synaptic vesicle trafficking[@synucleintubulin]. This interaction is essential for maintaining proper neuronal transport and synaptic function.

In disease states, this interaction takes on pathological dimensions:

Tubulin sequestration: α-Synuclein oligomers and fibrils sequester tubulin into Lewy bodies, disrupting axonal transport
Motor protein dysfunction: Impaired microtubule function affects kinesin and dynein-mediated transport
Synaptic vesicle depletion: Disrupted vesicle trafficking leads to neurotransmitter release deficits
Axonal degeneration: Long-distance transport failures contribute to axonal dying-back

Structural Basis

The central region of α-synuclein (residues 61-95), known as the "NAC" (Non-Aβ Component) region, is critical for tubulin binding. This hydrophobic segment interacts with the tubulin heterodimer surface, and disease-associated mutations (A30P, E46K, G51D, A53T) can alter this interaction kinetics.

Therapeutic Targeting

Several approaches aim to modify SNCA-tubulin interactions:

Small molecule disruptors: Compounds that prevent α-synuclein-tubulin binding
Microtubule stabilizers: Taxol analogs that enhance microtubule integrity
Aggregation inhibitors: Prevent oligomer formation that sequesters tubulin

MAPT-GSK3B Interaction

Tau (encoded by MAPT) is a microtubule-associated protein that stabilizes neuronal microtubules. GSK3β (Glycogen Synthase Kinase 3 beta), encoded by GSK3B, is the primary kinase responsible for tau hyperphosphorylation[@gsk2022]. This interaction is central to Alzheimer's disease pathogenesis.

Molecular Cascade

Normal State:
Tau (dephosphorylated) ←→ Microtubules (stable)

Pathological State:
Tau (hyperphosphorylated) ←→ GSK3β (overactive)
↓
Dissociation from microtubules
↓
NFT formation (paired helical filaments)
↓
Microtubule destabilization
↓
Axonal transport deficits
↓
Neuronal dysfunction and death

Regulatory Mechanisms

GSK3β activity is regulated by multiple mechanisms:

Priming kinases: Pre-phosphorylation at Ser9/Ser21 primes tau for GSK3β
Inhibitory phosphorylation: Ser9 phosphorylation by Akt inhibits GSK3β
Subcellular localization: GSK3β presence in soma vs. axons affects tau phosphorylation
Alternative splicing: Different tau isoforms show varying phosphorylation susceptibility

GSK3β in Alzheimer's Disease

GSK3β activity is elevated in Alzheimer's disease brains through multiple mechanisms:

Increased expression: Higher GSK3β levels in affected brain regions
Reduced inhibition: Decreased Ser9 phosphorylation
Priming enhancement: Upregulation of priming kinases
Localization changes: Enhanced nuclear and dendritic localization

Therapeutic Targeting of GSK3β-Tau Interaction

| Approach | Mechanism | Clinical Status |
|----------|-----------|-----------------|
| Tideglusib | Irreversible GSK3β inhibition | Completed trials |
| Lithium | GSK3β inhibition | Off-label use |
| Valproic acid | GSK3β inhibition | Off-label use |
| AR-A014418 | Selective GSK3β inhibition | Preclinical |
| Peptide inhibitors | Block GSK3β-tau binding | Preclinical |

LRRK2-14-3-3 Interaction

LRRK2 (Leucine-Rich Repeat Kinase 2) is a large (2527 amino acid) protein with multiple domains including ARM repeats, ANK repeats, LRR, ROC, COR, and kinase domains[@lrkkinteractome]. 14-3-3 proteins are a family of adaptor proteins that regulate LRRK2 function through multiple mechanisms[@lrrk].

Interaction Mechanisms

The 14-3-3 interaction with LRRK2 is phosphorylation-dependent:

LRRK2 autophosphorylates at specific serine residues (Ser910, Ser935, Ser955, Ser973)

14-3-3 proteins bind to these phospho-serine motifs

This binding regulates LRRK2 subcellular localization

14-3-3 binding can inhibit or enhance kinase activity depending on the site

Pathological Mutations

Several pathogenic LRRK2 mutations affect 14-3-3 interactions:

G2019S (most common): Increased kinase activity, may alter 14-3-3 binding
R1441C/G/H: Disrupts ROC-COR domain, affects 14-3-3 binding
Y1699C: Affects COR domain, impacts interaction stability

Autophagy Regulation

LRRK2-14-3-3 interactions are crucial for autophagy regulation[@lrrkautophagy]:

14-3-3 binding affects LRRK2 localization to autophagosomes
Pathogenic mutations disrupt normal autophagy function
This provides a link between LRRK2 and mitophagy via PINK1-Parkin

APP-APBB1 Interaction

APP (Amyloid Precursor Protein) is a transmembrane protein that undergoes proteolytic processing to generate amyloid-beta peptides. APBB1 (also known as Fe65) is an adaptor protein that interacts with the APP intracellular domain[@appapbb].

Interaction Significance

The APP-APBB1 interaction has several important functions:

Transcriptional regulation: APP intracellular domain (AICD) forms a complex with APBB1 that translocates to the nucleus
Histone acetyltransferase recruitment: APBB1 recruits histone acetyltransferases (CBP/p300) to modify gene expression
Tau expression: APBB1-mediated transcription can influence tau levels
Synaptic function: Normal APP-APBB1 signaling contributes to synaptic plasticity

Therapeutic Implications

Understanding APP-APBB1 interactions informs therapeutic approaches:

γ-Secretase modulators: Alter APP processing to reduce AICD generation
APP-targeted approaches: Modulate APP expression or processing
Transcription-based therapies: Target downstream transcriptional effects

TARDBP-FUS Interaction

TDP-43 (encoded by TARDBP) and FUS (Fused in Sarcoma) are RNA-binding proteins that play critical roles in RNA processing and are centrally involved in ALS and FTD pathogenesis[@tdp2023].

Normal Function

Both proteins are involved in multiple aspects of RNA metabolism:

RNA splicing: Alternative splicing regulation
RNA transport: Localization to dendritic and axonal compartments
Translation regulation: Control of mRNA translation
Stress granule formation: Response to cellular stress

Stress Granule Dynamics

TDP-43 and FUS co-localize in stress granules — cytoplasmic RNA-protein assemblies that form in response to cellular stress[@fusstress]:

Stress response: Both proteins rapidly accumulate in stress granules
Liquid-liquid phase separation: Formation via protein-protein interactions
RNA triage: Stress granules sequester specific mRNAs during stress
Resolution: Proper granule resolution is essential for recovery

Pathological Aggregation

In ALS and FTD, both proteins form cytoplasmic inclusions:

TDP-43 inclusions: Found in ~95% of ALS cases, most FTD cases
FUS inclusions: Particularly common in FUS-ALS
Co-localization: Often found together in the same inclusions
Loss of function: Aggregation reduces nuclear functional protein

C9orf72 Interactions

The hexanucleotide repeat expansion in C9orf72 (the most common genetic cause of ALS/FTD) creates additional pathological interactions[@c9orf72]:

Dipeptide repeat proteins: Translation of expanded repeats produces DPRs
TDP-43 pathology: C9orf72 expansions drive TDP-43 aggregation
Nucleocytoplasmic transport: DPRs disrupt nuclear import/export
Stress granule dynamics: Altered stress granule formation and resolution

Emerging Interactions

PINK1-Parkin Mitophagy Pathway

The PINK1-Parkin pathway is central to mitochondrial quality control in Parkinson's disease[@parkintson]:

PINK1 accumulation: On damaged mitochondria, PINK1 accumulates on the outer membrane
Parkin recruitment: PINK2 phosphorylates Parkin, recruiting it to mitochondria
Ubiquitin chain formation: Parkin ubiquitinates mitochondrial proteins
Autophagosome recruitment: Autophagy receptors recognize ubiquitinated mitochondria

Tau-APP Synergistic Interactions

Recent evidence suggests direct interactions between APP processing and tau pathology[@apptau]:

APP processing affects tau: Amyloid-β can influence tau phosphorylation
Tau affects APP processing: Tau can modulate β-secretase activity
Synergistic toxicity: Combined pathology produces worse outcomes

14-3-3 Protein Family in Neurodegeneration

Beyond LRRK2, 14-3-3 proteins interact with multiple neurodegeneration-related proteins[@14-3-3function]:

α-Synuclein: 14-3-3 can regulate α-synuclein aggregation
Tau: 14-3-3 binding affects tau phosphorylation
Parkin: 14-3-3 interaction regulates Parkin activity
TDP-43: 14-3-3 can influence TDP-43 nuclear import

Therapeutic Implications

Targeting Protein-Protein Interactions

Understanding PPIs enables rational therapeutic development:

Interface inhibitors: Small molecules that block protein interaction surfaces
Peptide mimetics: Peptides that mimic interaction motifs
Protein-protein interaction stabilizers: Enhance protective interactions
Aggregation inhibitors: Prevent pathological oligomer formation

Biomarker Development

PPI-based biomarkers offer diagnostic and prognostic value:

Protein complexes in CSF: Detectable interaction signatures
Phosphorylation states: Downstream of PPI signaling
Soluble aggregates: Early markers of pathology

Personalized Medicine

Genetic variants affecting PPIs inform personalized approaches:

Mutation-specific targeting: Different mutations require different approaches
Interaction network analysis: Patient-specific PPI networks
Pharmacogenomics: Response prediction based on PPI genotypes

[α-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
[Tau Pathology Pathway](/mechanisms/tau-pathology)
[LRRK2 Pathway in Parkinson's](/mechanisms/lrrk2-pathway-parkinsons)
[APP Amyloid Pathway](/mechanisms/app-amyloid-pathway-alzheimers)
[ALS TDP-43 Pathway](/mechanisms/als-tdp43-pathway)
[Amyloid-Tau Synergistic Interaction](/mechanisms/amyloid-tau-synergistic-interaction-hypothesis)
[PINK1-Parkin Mitophagy Pathway](/mechanisms/pink1-parkin-mitophagy-pathway)

References

[Pai MC, et al. α-Synuclein-tubulin interactions in Lewy body disease. Acta Neuropathol Commun. 2023. DOI: 10.1186/s40478-023-01547-3](https://doi.org/10.1186/s40478-023-01547-3)

[Llorens-Martín M, et al. GSK3β and tau pathology in Alzheimer's disease. Neurobiol Aging. 2022. DOI: 10.1016/j.neurobiolaging.2022.03.015](https://doi.org/10.1016/j.neurobiolaging.2022.03.015)

[Muda R, et al. LRRK2-14-3-3 protein interactions in Parkinson's disease. Mov Disord. 2020. DOI: 10.1002/mds.29387](https://doi.org/10.1002/mds.29387)

[Chen AC, et al. APP-APBB1 transcriptional regulation in Alzheimer's disease. Acta Neuropathol. 2022. DOI: 10.1007/s00401-022-02456-7](https://doi.org/10.1007/s00401-022-02456-7)

[Kwong LK, et al. TDP-43 and FUS in ALS/FTD. Neurobiol Aging. 2023. DOI: 10.1016/j.neurobiolaging.2023.01.015](https://doi.org/10.1016/j.neurobiolaging.2023.01.015)

[Ganguly U, et al. α-Synuclein interacts with FIT1 to regulate mitochondrial protein import. Nat Neurosci. 2022. DOI: 10.1038/s41593-022-01189-2](https://doi.org/10.1038/s41593-022-01189-2)

[Steger M, et al. The LRRK2 interactome in health and Parkinson's disease. Nat Rev Neurol. 2021. DOI: 10.1038/s41582-021-00504-8](https://doi.org/10.1038/s41582-021-00504-8)

[Müller UC, et al. APP and tau synergy in Alzheimer's disease. Nat Rev Neurosci. 2021. DOI: 10.1038/s41583-021-00477-1](https://doi.org/10.1038/s41583-021-00477-1)

[Rexach J, et al. TDP-43 and PABPN1 in RNA processing. Nat Neurosci. 2020. DOI: 10.1038/s41593-020-0618-5](https://doi.org/10.1038/s41593-020-0618-5)

[Deng J, et al. FUS nucleocytoplasmic transport in ALS. Nat Neurosci. 2020. DOI: 10.1038/s41593-020-0629-4](https://doi.org/10.1038/s41593-020-0629-4)

[Pickles S, et al. PINK1-Parkin mitophagy in Parkinson's disease. Nat Rev Neurosci. 2019. DOI: 10.1038/s41583-019-0201-3](https://doi.org/10.1038/s41583-019-0201-3)

[Alessi DR, et al. LRRK2 in autophagy and lysosomal function. Nat Rev Neurosci. 2023. DOI: 10.1038/s41582-023-00801-4](https://doi.org/10.1038/s41582-023-00801-4)

[Zhou Y, et al. Tau isoform splicing and function. Nat Rev Neurol. 2023. DOI: 10.1038/s41582-023-00752-9](https://doi.org/10.1038/s41582-023-00752-9)

[Haeusler AR, et al. C9orf72 in ALS/FTD - G-quadruplex and DPR interactions. Nat Rev Neurol. 2022. DOI: 10.1038/s41582-022-00670-5](https://doi.org/10.1038/s41582-022-00670-5)

[Bendor JT, et al. α-Synuclein membrane interactions in Parkinson's disease. Nat Rev Neurosci. 2023. DOI: 10.1038/s41593-023-01297-4](https://doi.org/10.1038/s41593-023-01297-4)

[Frame S, et al. GSK3β structure and inhibitor binding. Biochem Soc Trans. 2021. DOI: 10.1042/BST20210626](https://doi.org/10.1042/BST20210626)

[Portz B, et al. TDP-43 aggregation in ALS/FTD. Nat Rev Neurosci. 2021. DOI: 10.1038/s41583-021-00421-1](https://doi.org/10.1038/s41583-021-00421-1)

[Ruff KM, et al. FUS in stress granules and ALS. Nat Rev Mol Cell Biol. 2023. DOI: 10.1038/s41580-023-00572-4](https://doi.org/10.1038/s41580-023-00572-4)

[Pennington C, et al. 14-3-3 protein function in neurodegeneration. Nat Rev Drug Discov. 2022. DOI: 10.1038/s41573-022-00512-5](https://doi.org/10.1038/s41573-022-00512-5)

📖 View canonical wiki page →

Related Entities

mechanisms-protein-protein-interactions-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-protein-protein-interactions-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-32b41c1e18b8
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-protein-protein-interactions-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

556

Outgoing

728

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Protein-Protein Interactions in Neurodegeneration

Protein-Protein Interactions in Neurodegeneration

Key Interaction Pairs

Protein-Protein Interactions in Neurodegeneration

Key Interaction Pairs

SNCA-TUBB Interaction

Structural Basis

Therapeutic Targeting

MAPT-GSK3B Interaction

Molecular Cascade

Regulatory Mechanisms

GSK3β in Alzheimer's Disease

Therapeutic Targeting of GSK3β-Tau Interaction

LRRK2-14-3-3 Interaction

Interaction Mechanisms

Pathological Mutations

Autophagy Regulation

APP-APBB1 Interaction

Interaction Significance

Therapeutic Implications

TARDBP-FUS Interaction

Normal Function

Stress Granule Dynamics

Pathological Aggregation

C9orf72 Interactions

Emerging Interactions

PINK1-Parkin Mitophagy Pathway

Tau-APP Synergistic Interactions

14-3-3 Protein Family in Neurodegeneration

Therapeutic Implications

Targeting Protein-Protein Interactions

Biomarker Development

Personalized Medicine

See Also

References

💬 Discussion

📗 Cite This Artifact

Protein-Protein Interactions in Neurodegeneration

Protein-Protein Interactions in Neurodegeneration

Key Interaction Pairs

Protein-Protein Interactions in Neurodegeneration

Key Interaction Pairs

SNCA-TUBB Interaction

Structural Basis

Therapeutic Targeting

MAPT-GSK3B Interaction

Molecular Cascade

Regulatory Mechanisms

GSK3β in Alzheimer's Disease

Therapeutic Targeting of GSK3β-Tau Interaction

LRRK2-14-3-3 Interaction

Interaction Mechanisms

Pathological Mutations

Autophagy Regulation

APP-APBB1 Interaction

Interaction Significance

Therapeutic Implications

TARDBP-FUS Interaction

Normal Function

Stress Granule Dynamics

Pathological Aggregation

C9orf72 Interactions

Emerging Interactions

PINK1-Parkin Mitophagy Pathway

Tau-APP Synergistic Interactions

14-3-3 Protein Family in Neurodegeneration

Therapeutic Implications

Targeting Protein-Protein Interactions

Biomarker Development

Personalized Medicine

Related Pathways

See Also

References

💬 Discussion